Skip to content

Pulmonary vein isolation using focal pulsed field ablation versus very-high power short duration radiofrequency ablation: a quasi-randomized study

Pulmonary vein isolation using focal pulsed field ablation versus very-high power short duration radiofrequency ablation: a quasi-randomized study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00032756
Enrollment
100
Registered
2024-01-24
Start date
2023-07-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I48

Interventions

Group 1: Pulmonary vein isolation using focal pulsed field ablation. The patients in this group are undergoing the ablation of pulmonary veins using focal pulsed field ablation. The follow-up is 1 yea

Sponsors

Universitätsklinikum Düsseldorf
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Paroxysmal or persistent atrial fibrillation

Exclusion criteria

Exclusion criteria: Contraindications for oral anticoagulation Contraindications for the pulmonary vein isolation Left atrial diameter >6 cm Left atrial redo procedures

Design outcomes

Primary

MeasureTime frame
Freedom of atrial tachyarrhythmias during the first year after ablation. Per definition we search for sustained atrial arrhythmias over 30 seconds. The endpoint is assessed based on symptoms and using Holter ECGs. The Holter ECGs are planed at 3, 6 and 12 months after the procedure, as well as symptom-triggered.

Secondary

MeasureTime frame
Improvement of symptoms. We aim to document the change in AFEQT (AF Effect On Quality-Of-Life Questionnaire) questionnaire before and after the ablation (3,6 and 12 months). Safety - the intra- and postprocedural occurrence of major complications, defined as: pericardial tamponade, stroke, major groin complication, phrenic nerve injury, atrio-esophageal fistula.

Countries

Germany

Contacts

Public ContactObaida Rana

Universitätsklinikum Düsseldorf

obaida.rana@med.uni-duesseldorf.de+49 211 81 18800

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026